Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Interest & Investment Income of $1.2 million for Q1 2026, up 3.8% on a QoQ basis from $1.2 million in Q3 2025, and up 2.3% year-over-year from $1.2 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- Quarterly Interest & Investment Income rose 2.3% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 63.73% YoY) and the FY2024 annual result came in at $5.3 million, up 266150.0% from the prior year.
- Interest & Investment Income was $1.2 million for Q1 2026 at Xeris Biopharma Holdings, up from $1.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $5.3 million in Q4 2024 and bottomed at -$3.6 million in Q4 2023.
- A 5-year average of $566733.3 and a median of $68000.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income slumped 30483.33% — and 2024, when it surged 32150.0%.
- Xeris Biopharma Holdings' Interest & Investment Income stood at $12000.0 in 2022, then slumped by 30483.33% to -$3.6 million in 2023, then jumped by 245.69% to $5.3 million in 2024, then tumbled by 78.2% to $1.2 million in 2025, then gained by 3.8% to $1.2 million in 2026.
- Business Quant data shows XERS's Interest & Investment Income at $1.2 million in Q1 2026, $1.2 million in Q3 2025, and $1.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 1.92 Mn |
| Dec 31, 2023 | -3.65 Mn |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | -49,000.00 |
| Mar 31, 2023 | -6,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Mar 31, 2022 | 68,000.00 |
| Dec 31, 2021 | -281,000.00 |
| Sep 30, 2021 | 66,000.00 |
| Jun 30, 2021 | 77,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Dec 31, 2020 | 2.02 Mn |